HLB Prepares for ESMO... "Will Collaborate with European Pharmaceutical Companies"

Setting Up Booths Inside the Event Venue

HLB announced on the 15th that its U.S. subsidiary Elevar will participate in the European Society for Medical Oncology (ESMO 2023), held in Madrid, Spain, from the 20th to the 24th of next month for five days.

HLB logo. [Image provided by HLB]

Elevar added that during the event, it plans to discuss partnerships with major European pharmaceutical companies for the distribution and sales of Lenvatinib within Europe. To this end, a large booth will be set up at the venue, and negotiations will be conducted with pharmaceutical companies that have already expressed interest.

HLB aims to complete commercialization preparations as quickly as possible while the U.S. Food and Drug Administration (FDA) conducts the new drug review for the liver cancer treatment Lenvatinib, so that sales can proceed promptly after approval. Accordingly, it has already secured pharmaceutical sales licenses in 12 states, including New Jersey, in the U.S.

With commercialization preparations progressing smoothly in the U.S., HLB stated that it will implement a two-track strategy to simultaneously advance regulatory approval and sales preparations in Europe starting with this ESMO event. It also added that it is in discussions with its partner Hansoh Pharmaceutical to submit a marketing authorization application to the European Medicines Agency (EMA).

Separately, clinical results from a Phase 1b/2 clinical trial combining Lenvatinib and Lonserf for metastatic colorectal cancer patients will also be presented in poster format at this event.

HLB also revealed that as the approval of the liver cancer drug becomes more visible, it is reviewing indications for which new drug development can proceed rapidly following liver cancer. The company plans to comprehensively review clinical results for various indications, including those from clinical trials of Lenvatinib conducted by Hansoh Pharmaceutical in China, and proceed with subsequent clinical trials.

Jin Yang-gon, Chairman of HLB, said at the 'Korea Investment Week 2023' forum held on the 12th, "Lenvatinib is evaluated as an effective liver cancer treatment, and once it debuts in the global pharmaceutical market, active combination clinical trials with drugs owned by major pharmaceutical companies will begin in earnest." He added, "There are already six indications in Phase 3 clinical trials in China, and the potential for additional global clinical trials is very high. Approval of the liver cancer treatment will be a turning point that overwhelmingly changes the corporate value."

Meanwhile, HLB is also working to expand Lenvatinib, which has already been approved in China as a second-line treatment for liver cancer and a third-line treatment for stomach cancer, to Southeast Asian countries including Singapore through cooperation with Hansoh Pharmaceutical.

This content was produced with the assistance of AI translation services.